Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)Depreciation ExpenseEBIATGross ProfitLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Vivos Therapeutics (VVOS) Shares Outstanding (2019 - 2025)

Vivos Therapeutics has reported Shares Outstanding over the past 7 years, most recently at $9.3 million for Q4 2025.

  • Quarterly Shares Outstanding rose 57.68% to $9.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $9.3 million through Dec 2025, up 57.68% year-over-year, with the annual reading at $9.3 million for FY2025, 57.68% up from the prior year.
  • Shares Outstanding was $9.3 million for Q4 2025 at Vivos Therapeutics, up from $8.3 million in the prior quarter.
  • Over five years, Shares Outstanding peaked at $23.0 million in Q3 2021 and troughed at $920592.0 in Q4 2021.
  • The 5-year median for Shares Outstanding is $3.1 million (2024), against an average of $6.1 million.
  • Year-over-year, Shares Outstanding surged 10827.7% in 2021 and then tumbled 96.0% in 2022.
  • A 5-year view of Shares Outstanding shows it stood at $920592.0 in 2021, then changed by 0.0% to $920592.0 in 2022, then skyrocketed by 99.21% to $1.8 million in 2023, then soared by 221.15% to $5.9 million in 2024, then soared by 57.68% to $9.3 million in 2025.
  • Per Business Quant, the three most recent readings for VVOS's Shares Outstanding are $9.3 million (Q4 2025), $8.3 million (Q3 2025), and $7.3 million (Q2 2025).